By: Jeanne Lenzer
BMJ 2010; 341:c7009 doi: 10.1136/bmj.c7009 (Published 6 December 2010)
Cite this as: BMJ 2010; 341:c7009
The British Columbian government is terminating its contract for drug reviews with an independent drug watchdog organisation, instead allowing drug manufacturers and people with financial ties to the industry to advise. The move comes after years of pressure from the industry group Canada’s Research-Based Pharmaceutical Companies for a more “open” process for reviewing drugs.